Astrana Health, Inc. (ASTH) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
↓
21.02
↑+21% vs avg
5yr avg: 17.33
30Y Low5.9·High30.7
P/FCF
↓
18.79
↓-48% vs avg
5yr avg: 35.93
30Y Low11.7·High65.3
P/B Ratio
↓
3.50
-5% vs avg
5yr avg: 3.70
30Y Low1.5·High6.5
ROE
↓
4.2%
↑-57% vs avg
5yr avg: 9.8%
30Y Low-109%·High15%
Debt/EBITDA
↑
8.68
↑+123% vs avg
5yr avg: 3.89
30Y Low0.1·High10.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ASTH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Astrana Health, Inc. trades at 86.1x earnings, 119% above its 5-year average of 39.4x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 289%. On a free-cash-flow basis, the stock trades at 18.8x P/FCF, 48% below the 5-year average of 35.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.2B | $1.5B | $1.8B | $1.3B | $3.3B | $684M | $670M | $753M | $688M | $31M |
| Enterprise Value | $2.6B | $1.9B | $1.7B | $1.8B | $1.3B | $3.3B | $751M | $824M | $659M | $574M | $22M |
| P/E Ratio → | 86.07 | 53.93 | 35.03 | 29.69 | 29.89 | 48.34 | 18.09 | 47.21 | 68.45 | 26.67 | — |
| P/S Ratio | 0.62 | 0.38 | 0.75 | 1.30 | 1.18 | 4.31 | 1.85 | 1.20 | 1.45 | 1.92 | 0.70 |
| P/B Ratio | 3.50 | 2.19 | 2.96 | 4.39 | 2.42 | 6.53 | 1.54 | 1.86 | 1.85 | 2.05 | 3.61 |
| P/FCF | 18.79 | 11.72 | 34.43 | 45.41 | 22.80 | 65.27 | 15.20 | 53.06 | 30.18 | 13.49 | — |
| P/OCF | 17.13 | 10.69 | 29.13 | 26.42 | 16.43 | 47.43 | 14.82 | 49.02 | 28.83 | 12.96 | — |
P/E links to full P/E history page with 30-year chart
ASTH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Astrana Health, Inc.'s enterprise value stands at 21.0x EBITDA, 21% above its 5-year average of 17.3x. The Healthcare sector median is 14.2x, placing the stock at a 48% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.59 | 0.84 | 1.32 | 1.13 | 4.27 | 2.03 | 1.47 | 1.27 | 1.61 | 0.50 |
| EV / EBITDA | 21.02 | 15.08 | 14.53 | 17.88 | 10.60 | 28.56 | 30.74 | 16.24 | 5.91 | 10.14 | — |
| EV / EBIT | 33.26 | 23.86 | 14.96 | 17.27 | 13.65 | 39.74 | 65.94 | 26.94 | 7.93 | 11.54 | — |
| EV / FCF | — | 17.93 | 38.58 | 46.10 | 21.81 | 64.64 | 16.70 | 65.20 | 26.45 | 11.26 | — |
ASTH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Astrana Health, Inc. earns an operating margin of 2.5%. Operating margins have compressed from 6.1% to 2.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 4.2% is modest. ROIC of 6.2% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 9.3% | 9.3% | 13.3% | 15.5% | 17.4% | 23.0% | 5.9% | 16.6% | 26.8% | 17.9% | 22.0% |
| Operating Margin | 2.5% | 2.5% | 4.4% | 6.1% | 9.1% | 12.7% | 1.6% | 5.8% | 17.7% | 10.5% | -14.9% |
| Net Profit Margin | 0.7% | 0.7% | 2.1% | 4.4% | 3.9% | 8.9% | -6.4% | 2.5% | 2.1% | 7.2% | -21.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.2% | 9.3% | 12.5% | 8.4% | 14.4% | -5.9% | 3.7% | 2.9% | 15.0% | -109.3% |
| ROA | 1.3% | 1.3% | 3.8% | 6.4% | 4.9% | 8.2% | -3.1% | 2.3% | 2.2% | 10.1% | -47.8% |
| ROIC | 6.2% | 6.2% | 11.8% | 13.5% | 16.0% | 14.9% | 0.9% | 5.9% | 25.8% | 25.4% | — |
| ROCE | 6.1% | 6.1% | 10.5% | 11.0% | 13.3% | 13.5% | 0.9% | 6.1% | 22.4% | 19.1% | -54.2% |
ASTH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Astrana Health, Inc. carries a Debt/EBITDA ratio of 8.7x, which is highly leveraged (169% above the sector average of 3.2x). Net debt stands at $649M ($1.1B total debt minus $429M cash). Interest coverage of just 1.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.93 | 1.93 | 0.92 | 0.78 | 0.41 | 0.39 | 0.59 | 0.71 | 0.03 | 0.02 | 0.02 |
| Debt / EBITDA | 8.68 | 8.68 | 4.02 | 3.14 | 1.88 | 1.74 | 10.66 | 5.06 | 0.12 | 0.11 | — |
| Net Debt / Equity | — | 1.16 | 0.36 | 0.07 | -0.11 | -0.06 | 0.15 | 0.42 | -0.23 | -0.34 | -1.06 |
| Net Debt / EBITDA | 5.22 | 5.22 | 1.56 | 0.27 | -0.48 | -0.28 | 2.75 | 3.02 | -0.84 | -2.00 | — |
| Debt / FCF | — | 6.21 | 4.15 | 0.69 | -0.99 | -0.63 | 1.49 | 12.14 | -3.74 | -2.23 | — |
| Interest Coverage | 1.57 | 1.57 | 3.44 | 6.58 | 11.94 | 15.41 | 4.51 | 6.46 | 148.41 | 624.81 | -14.20 |
ASTH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.40x means Astrana Health, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.11x to 1.40x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.40 | 1.40 | 1.75 | 2.11 | 2.88 | 3.53 | 2.94 | 3.12 | 2.40 | 1.32 | 1.82 |
| Quick Ratio | 1.40 | 1.40 | 1.75 | 2.11 | 2.88 | 3.53 | 2.94 | 3.12 | 2.40 | 1.32 | 1.82 |
| Cash Ratio | 0.70 | 0.70 | 0.80 | 1.36 | 1.98 | 2.50 | 2.27 | 2.08 | 1.50 | 1.10 | 1.25 |
| Asset Turnover | — | 1.43 | 1.50 | 1.49 | 1.18 | 0.89 | 0.45 | 0.77 | 1.01 | 0.73 | 2.25 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 46.76 | 58.27 | 38.89 | 38.20 | 46.84 | 59.76 | 64.42 | 40.34 | 20.53 | 33.10 |
ASTH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Astrana Health, Inc. returns 1.2% to shareholders annually — split between a 0.4% dividend yield and 0.8% buyback yield. The payout ratio of 35.1% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 1.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.6% | 0.3% | 3.4% | 1.0% | 0.9% | 7.5% | 9.2% | 2.4% | 1.5% | — |
| Payout Ratio | 35.1% | 35.1% | 9.4% | 102.2% | 31.1% | 45.1% | — | 437.2% | 163.9% | 40.5% | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.2% | 1.9% | 2.9% | 3.4% | 3.3% | 2.1% | 5.5% | 2.1% | 1.5% | 3.8% | — |
| FCF Yield | 5.3% | 8.5% | 2.9% | 2.2% | 4.4% | 1.5% | 6.6% | 1.9% | 3.3% | 7.4% | — |
| Buyback Yield | 0.8% | 1.3% | 0.1% | 0.6% | 0.7% | 0.2% | 0.1% | 1.1% | 0.7% | 0.5% | 0.0% |
| Total Shareholder Yield | 1.2% | 1.9% | 0.3% | 4.0% | 1.7% | 1.1% | 7.6% | 10.3% | 3.0% | 2.0% | 0.0% |
| Shares Outstanding | — | $49M | $48M | $47M | $46M | $45M | $37M | $36M | $38M | $29M | $5M |
Peer Comparison
Compare ASTH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ASTHYou | $2B | 86.1 | 21.0 | 18.8 | 9.3% | 2.5% | 4.2% | 6.2% | 8.7 |
 ALHC | $4B | -5754.1 | 90.9 | 38.4 | 12.4% | 0.4% | -0.5% | — | 7.5 |
 CLOV | $3B | -30.2 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 OSCR | $7B | -16.9 | — | 7.0 | 14.4% | -3.4% | -44.4% | — | — |
 WELL | $148B | 152.1 | 66.0 | 52.0 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 |
 AGL | $2B | -4.6 | — | — | -3.2% | -7.1% | -135.6% | -203.2% | — |
 DOCS | $4B | 20.5 | 16.5 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 PRVA | $3B | 130.5 | 56.4 | 18.2 | 9.9% | 1.6% | 3.1% | 9.9% | 0.2 |
 UNH | $369B | 30.7 | 18.1 | 23.0 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
 CVS | $129B | 72.9 | 14.3 | 16.6 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 CI | $74B | 12.7 | 8.3 | 8.9 | 9.5% | 3.3% | 14.3% | 10.4% | 2.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ASTH — Frequently Asked Questions
Quick answers to the most common questions about buying ASTH stock.
What is Astrana Health, Inc.'s P/E ratio?
Astrana Health, Inc.'s current P/E ratio is 86.1x. The historical average is 39.7x. This places it at the 100th percentile of its historical range.
What is Astrana Health, Inc.'s EV/EBITDA?
Astrana Health, Inc.'s current EV/EBITDA is 21.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.6x.
What is Astrana Health, Inc.'s ROE?
Astrana Health, Inc.'s return on equity (ROE) is 4.2%. The historical average is -4.5%.
Is ASTH stock overvalued?
Based on historical data, Astrana Health, Inc. is trading at a P/E of 86.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Astrana Health, Inc.'s dividend yield?
Astrana Health, Inc.'s current dividend yield is 0.40% with a payout ratio of 35.1%.
What are Astrana Health, Inc.'s profit margins?
Astrana Health, Inc. has 9.3% gross margin and 2.5% operating margin.
How much debt does Astrana Health, Inc. have?
Astrana Health, Inc.'s Debt/EBITDA ratio is 8.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.